A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
Part of paid clinical trials in Palo Alto, California.
- Sponsor
- Quan Dong Nguyen
- Study ID
- NCT07427628
- Phase
- PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Non Infectious Uveitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- TRX103 — BIOLOGICALTRX103 infusion via peripheral line
Study Details
The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.
Key Dates
- Start date
- Mar 31, 2026
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 18 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: TRX-103 InpatientInfusion of TRX103 followed by 8 hour in patient observation period
- Experimental: TRX-103 OutpatientOutpatient Infusion of TRX103 followed by outpatient observation period
Primary Outcome Measure
Incidence of Treatment emergent Adverse events and Serious Adverse events at week 52 [ Time Frame: Up to a year ]
Central Contacts
- PEACOCX Study Team650-497-2078
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Byers Eye Institute | Palo Alto | California | 94303 |
Find similar trials in Palo Alto, CA
By research site